Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Concepcion

Hematology & Oncology San Juan, PR Medical Doctor

NPI 1699183129 CMS profile 1236724

715 Ave Ponce De Leon Parada 37.5, San Juan, PR 00917

Open in the dashboard

General payments

$13,956

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Concepcion of San Juan, PR is reported in the CMS Open Payments database as having received $13,956 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,570 59
2024 General $2,740 73
2023 General $3,530 81
2022 General $2,442 61
2021 General $2,546 56
2020 General $522 21
2019 General $606 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Concepcion
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Jose Concepcion were reported at $1,570. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Jose Concepcion Hematology & Oncology median Middle half National median
2019 $606 $529 $121–$2,516 $163
2020 $522 $339 $82–$2,213 $114
2021 $2,546 $263 $49–$1,965 $132
2022 $2,442 $416 $103–$2,395 $149
2023 $3,530 $542 $125–$2,646 $160
2024 $2,740 $692 $141–$3,008 $164
2025 $1,570 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,943 31 payments
  2. E.R. Squibb & Sons, L.L.C. $903 25 payments
  3. Genzyme Corporation $848 16 payments
  4. Janssen Pharmaceuticals, Inc $709 29 payments
  5. AbbVie, Inc. $588 18 payments
  6. Eisai Inc. $578 14 payments
  7. AstraZeneca Pharmaceuticals LP $574 26 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $486 6 payments
  9. Astellas Pharma US Inc $482 8 payments
  10. Rigel Pharmaceuticals, Inc. $438 6 payments
  11. Other $6,407 184 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,175 355 payments
  2. Education $781 8 payments
Products named General payments · program years 2019–2025
  1. Kyprolis $890 16 payments
  2. Lenvima $578 14 payments
  3. VENCLEXTA $524 15 payments
  4. SARCLISA $516 9 payments
  5. Blincyto $502 10 payments
  6. XGEVA $461 13 payments
  7. OPDIVO $455 12 payments
  8. MONJUVI $444 6 payments
  9. Tavalisse $438 6 payments
  10. EPKINLY $396 9 payments
  11. Other $10,439 376 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record